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Abstract
Purpose The purposes of this paper were to present the
current status of contrast-enhanced transrectal ultrasound
imaging and to discuss the latest achievements and tech-
niques now under preclinical testing.
Objective Although grayscale transrectal ultrasound is
the standard method for prostate imaging, it lacks accuracy
in the detection and localization of prostate cancer. With
the introduction of contrast-enhanced ultrasound (CEUS),
perfusion imaging of the microvascularization became
available. By this, cancer-induced neovascularisation can
be visualized with the potential to improve ultrasound
imaging for prostate cancer detection and localization
signiﬁcantly. For example, several studies have shown that
CEUS-guided biopsies have the same or higher PCa
detection rate compared with systematic biopsies with less
biopsies needed.
Materials and methods This paper describes the current
status of CEUS and discusses novel quantiﬁcation
techniques that can improve the accuracy even further.
Furthermore, quantiﬁcation might decrease the user-
dependency, opening the door to use in the routine clinical
environment. A new generation of targeted microbubbles is
now under pre-clinical testing and showed avidly binding
to VEGFR-2, a receptor up-regulated in prostate cancer due
to angiogenesis. The ﬁrst publications regarding a targeted
microbubble ready for human use will be discussed.
Conclusion Ultrasound-assisted drug delivery gives rise
to a whole new set of therapeutic options, also for prostate
cancer. A major breakthrough in the future can be expected
from the clinical use of targeted microbubbles for drug
delivery for prostate cancer diagnosis as well as treatment.
Keywords Contrast-enhanced ultrasound  Prostate
cancer  TRUS  Targeted microbubbles  Quantiﬁcation
Introduction
Prostate cancer (PCa) is the most common neoplasm in
men. In Europe, in 2008, the incidence rate was 214 cases
per 1,000 men, and this number is still rising with, e.g., the
increase in age [1]. In the European Union, prostate cancer
has about the same incidence as breast cancer [2]. For
breast cancer detection, suitable imaging techniques are
available and large-scale, image-based, screening programs
are active. However, for prostate cancer, no imaging
technique currently exists, which can accurately diagnose
and stage this malignancy. It is hoped that due to recent
developments in imaging, this will change in the near
future.
In MRI, functional assessment of the prostate is
advancing with techniques such as MR spectrometry,
dynamic contrast-enhanced MRI, and diffusion-weighted
MRI. Recently, Turkbey et al. [3] showed that with T2-
weighted MRI combined with dynamic contrast-enhanced
MRI and MR spectrometry at 3T, correct prostate cancer
staging could be achieved in 80% of the cases. However, a
large difference in, e.g., detection rate is seen between
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localization [4].
When compared with other medical imaging techniques,
ultrasound has many advantages such as the lack of using
ionizing radiation. Furthermore, it is cost-effective [5] and
can be used at the bedside. However, downsides of ultra-
sound are, for example, the user dependency and learning
curve. Although 3D imaging has already been introduced a
long time ago, mostly prostate ultrasound is still performed
in 2D.
The goals of this paper were to present the current status
of contrast-enhanced transrectal ultrasound imaging and to
discuss the latest achievements and techniques now under
preclinical testing.
Transrectal ultrasound (TRUS)
TRUS is the classical ultrasound technique for prostate
imaging and enables a detailed visualization of the pros-
tate. However, prostate cancer is hard to detect with stan-
dard grayscale TRUS. The classical signs for malignancy
are hypoechoic lesions, vesicular asymmetry, and capsular
irregularity; however, only 11–35% of the malignancies are
visible on grayscale TRUS [6]. Furthermore, of all hypo-
echoic lesions seen, only in 17–57% of the cases malig-
nancy is present [7]. Because of this low accuracy for the
diagnosis of PCa, TRUS is mainly used for volume mea-
surement and guidance of systematic biopsies. In conclu-
sion, transrectal grayscale ultrasound imaging lacks
accuracy in the diagnosis of prostate cancer, and therefore,
there is an urgent need for improvement in TRUS.
In an attempt to increase the diagnostic value of gray-
scale TRUS, Beerlage et al. tested a system for comput-
erized analysis of ultrasonographic prostate images:
AUDEX (Automated Urologic Diagnostic EXpert system).
They compared grayscale TRUS images octants with rad-
ical prostatectomy specimens. The AUDEX analysis
showed a diagnostic accuracy of 57%, and the authors
concluded that the system is thus inappropriate for routine
clinical use [8].
With the use of computerized transrectal ultrasound (C-
TRUS), Loch studied the detection rate of C-TRUS-guided
biopsies in men with previous negative systematic biopsies.
C-TRUS analyzes static TRUS images by using algorithms
based on reﬂected raw ultrasound data independent of
visual grayscale information. In 132 patients, 50% of
cancer was detected by C-TRUS-guided biopsies [9]. This
is a considerable high value as compared to known num-
bers of repeated systematic biopsies [10].
Another quantiﬁcation method developed for PCa
detection by TRUS is referred to as Histoscanning. Like
C-TRUS, it is a computerized analysis of TRUS data.
Braeckman et al. [11] studied 13 men before radical pro-
statectomy with Histoscanning and showed that in all men,
all lesions larger than 0.5 ml were detected. Although
promising, more data is needed from different patient
groups and different centers to determine the value in the
routine clinical environment.
Prostate malignant lesions are thought to consist of
stiffer tissue as compared to benign areas. Elastography is a
real-time imaging technique that detects these differences
in stiffness. Aigner et al. compared elastography-guided
biopsies with 10 core systematic biopsies in 94 men. They
showed that the detection rate of PCa was comparable,
21.3% in the elastography-guided and 19.1% in the sys-
tematic biopsies. With elastography, signiﬁcantly less
biopsies were taken (158 vs. 752) [12].
Prostate cancer induces neovascularistion, which results
in a disturbed perfusion of malignant tissue compared to
normal prostate tissue [13, 14]. If these changes in tissue
blood ﬂow could be visualized, the accuracy for detecting
PCa could potentially increase.
The ﬁrst discovered ultrasound technique for visualiza-
tion of blood ﬂow was Doppler, which images the relative
velocity of blood ﬂow. Sen et al. compared grayscale US
with color Doppler in targeted biopsies in 40 patients.
Respectively, they show a difference in sensitivity of 88.2
versus 73.5% and speciﬁcity of 66.6 versus 33.3% [15].
The main shortcoming of prostate color Doppler imaging is
the inability to visualize low blood ﬂow in small vessels,
especially in the microvasculature of tissue.
Power Doppler ultrasonography (PDU) increases the
sensitivity for the detection of blood ﬂow as compared to
color Doppler [16]. Sakayra et al. and Takahashi et al.
compared systematic biopsies with PDU imaging. A sen-
sitivity between 77 and 90% was seen, with an speciﬁcity
of 75–88% [16, 17]. Although color Doppler and power
Doppler are more likely to yield positive ﬁndings with
directed biopsy, still detection is insufﬁciently sensitive
and speciﬁc to obviate systematic biopsy. For better
imaging of low blood ﬂow and microvascular changes in
PCa, contrast-enhanced TRUS imaging was introduced.
Contrast-enhanced ultrasound
The currently used ultrasound contrast agents consist of a
solution of gas-ﬁlled microbubbles with a diameter in the
order of micrometers, smaller than red blood cells, and
stabilized with a shell. The bubbles stay inside the blood
pool and travel through the whole body through all blood
vessels, including the microvasculature. Clinically, con-
trast-enhanced ultrasound is now mainly used for perfusion
measurement of the heart and for the detection of liver
malignancies [18, 19].
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the diagnosis of prostate cancer was in combination with
Doppler imaging. Using contrast-enhanced ultrasound,
additional reﬂectors are added to the blood pool, thereby
increasing the sensitivity for detecting low ﬂow in small
vessels.
In 2001, Sedelaar et al. showed that increased micro-
vessel density (MVD) in malignant lesions could be
detected by contrast-enhanced power Doppler imaging.
They found that CEUS-enhanced areas had a 1.93 times
higher MVD as compared to the non-enhanced areas. Only
small satellite lesions of 1–2 mm diameter were not
detected [13].
Frauscher et al. compared contrast-enhanced color
Doppler (CECD)-targeted biopsies (CB) with systematic
biopsies (SB). In the CB group, 5 or less biopsies were
taken from contrast-enhancing areas, and in the SB group,
10 systematic biopsies were taken. Of 230 patients, PCa
was detected in 69 patients (30%), with CB in 56 patients
(24.4%), and with SB in 52 patients (22.6%). They con-
cluded that the same detection rate can be obtained with
less biopsies when CECD-guided biopsies are used [20]. In
2005, Pelzer et al. performed a combined approach of CB
and SB to investigate the impact on PCa detection. They
also showed that the detection rate is comparable with less
biopsies [21]. However, the papers also showed that from
all CB in only 1 out of 3 (Pelzer et al. 32%) to 4 (Fraucher
et al. 24%), PCa is found.
The last years, new advanced CEUS techniques became
available. These so-called contrast-speciﬁc imaging tech-
niques enable to differentiate between the non-linear sig-
nals reﬂected by the microbubbles and the linear signals
from the tissue. In this way, a contrast-only image can be
presented. Several different methods have been developed,
such as harmonic imaging, pulse inversion, CPS, and
power modulation. The techniques are capable of detecting
one single microbubble and therefore can visualize the
blood ﬂow in the microvasculature. Figure 1 shows several
images of contrast-speciﬁc imaging at different moments
after the intravenous injection of contrast.
Halpern et al. compared contrast-enhanced harmonic
imaging-targeted biopsies with systematic biopsy in 301
patients. CEUS-guided biopsies were 2 times more likely
to ﬁnd cancer compared to systematic biopsy in patients
with PCa. However, targeted biopsies missed 20% of
cancers, which were detected on systematic biopsy alone.
Fig. 1 Power modulation CEUS imaging. Each panel: left contrast-
only, right normal gray scale imaging. a 20 s after contrast injection.
The contrast-only image shows an almost black picture,
demonstrating optimal tissue suppression. b Start inﬂow of contrast
26 s after injection. c Peak enhancement 34 s after injection. d 107 s
after injection
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noma is higher with CEUS-guided biopsies, systematic
biopsies are still needed [22]. Sano et al. used harmonic
imaging to perform 12-core systematic and targeted biop-
sies in 41 patients. They also showed that signiﬁcantly
more cancers are found with CEUS-targeted biopsies: 36.6
versus 17.7% with systematic biopsies. Furthermore, a
comparison was made between radical prostatectomy
tumor locations and pre-operatively performed CEUS in 13
patients. In 10 patients, at least one tumor could be iden-
tiﬁed [23]. Matsumoto et al. compared radical prostatec-
tomy specimens with pre-operatively performed grayscale
US and harmonic imaging CEUS. In 50 patients, they were
able to identify at least one tumor focus in 40% of the cases
by grayscale imaging. When using CEUS alone, at least
one tumor focus enhancement was seen in 62% of the
patients, and when combined, in 80% of the cases, iden-
tiﬁcation of a tumor focus was possible [24].
In conclusion, the new contrast-speciﬁc ultrasound
techniques show promising results. However, one of the
downsides of CEUS is the subjective interpretation by the
investigator. For example, several different enhancement
patterns can correlate with the presence of PCa, and the
most important events to detect these enhancement patterns
take place within seconds. This makes the interpretation of
CEUS for prostate cancer difﬁcult outside the centers of
excellence. To overcome this problem, a more objective
and reliable interpretation by quantiﬁcation of CEUS is
needed.
Quantiﬁcation
The ﬁrst attempts for quantiﬁcation of CEUS in prostate
cancer used perfusion-related parameters. Goossen et al.
used power Doppler techniques to study the in- and outﬂow
characteristics after a bolus injection of contrast. For this,
they analyzed the time–intensity curve as measured by
the amount of colored pixels related to time. In 78% of the
cases, they were able to identify in which side of the
prostate the largest malignancy was located by analyzing
the time between injection and maximum peak of contrast
enhancement [25].
Recently, Zhu et al. investigated the use of hemody-
namic parameters measured using harmonic imaging in
103 patients to detect aggressiveness of PCa. ROIs were
drawn at systematic biopsy sites and areas of sonographic
abnormalities, e.g. heterogenous contrast ﬂow, abnormal
Doppler ﬂow, echotexture or contour deformity. The arri-
val time (AT), time to peak (TTP), and peak intensity for
these ROI curves were calculated. High-grade tumors had a
signiﬁcantly shorter AT and TTP than low-grade tumors
[26]. No signiﬁcant difference was detected between the
enhancement of low-grade tumors and non-malignant
tissue.
We propose an alternative quantiﬁcation method based
on the diffusion or dispersion of contrast agent in the tissue.
On a pixel basis, the spreading of contrast in the tissue is
determined using a mathematical model of diffusion. This
model is ﬁtted to measured time–intensity curves, and a
diffusion-related parameter is extracted. We hypothesize
that the intravascular diffusion or dispersion, as described
by the extracted diffusion parameter, correlates with the
microvascular structure and therefore correlates better with
angiogenesis than the traditional perfusion parameters. In a
preliminary evaluation in 4 patients scheduled for radical
prostatectomy, the correlation between the diffusion
parameter and the histology was determined. For an
example see Fig. 2. Based on a pixel comparison, the area
under the ROC curve was 0.909, which demonstrated to be
superior to that of any other measured perfusion-related
parameter as proposed in literature until now. This prom-
ising result has to be further conﬁrmed in larger studies.
In conclusion, quantiﬁcation could make an objective
and reliable interpretation of CEUS possible with a high
accuracy. Further scientiﬁc and clinical evidence is still
needed to judge the role of these techniques in a routine
clinical environment. One of the disadvantages is that most
of these quantiﬁcation techniques use 2D contrast imaging.
This implies that for every bolus of contrast, only 1 single
2D plane can be quantiﬁed. 3D/4D CEUS could solve this
limitation, and furthermore enable analysis of perfusion
and diffusion in 3D, which most probably will further
improve the accuracy of the techniques.
Fig. 2 Quantiﬁcation: parametric image of diffusion parameter. Blue
low diffusion, red high diffusion value
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A new generation of ultrasound contrast agent is made of
targeted microbubbles. These bubbles have the same gen-
eral features as traditional microbubbles; however, addi-
tional molecules that bind to speciﬁc intravascular
receptors are embedded in the shell of the bubble. Possible
receptor targets for prostate cancer are those that are
up-regulated during the process of angiogenesis. Most
research has been focusing on the vascular endothelial
growth factor (VEGF) receptors.
After an intravenous injection of targeted contrast,
bubbles will attach to the target receptors, and after some
time, the concentration of free ﬂoating microbubbles will
be signiﬁcantly lower than the concentration of the
attached bubbles in the tissue where the receptors are up-
regulated. After minutes, the attached bubbles can be
detected by contrast ultrasound imaging. A great advantage
of this technique is the larger time window for detecting
lesions; once the bubbles are bound, after approximately
7–10 min, the whole organ can be scanned for minutes.
The last years, investigations using targeted ultrasound
contrast have been performed in vitro as well as in vivo
[27–30]. Tardy et al. and Fischer et al. used a rat model to
investigate the contrast-enhancing effects of target-speciﬁc
microbubbles versus a non-speciﬁc contrast agent in
malignant prostatic tissue. They showed that more than
10 min after infusion of a low concentration of VEGFR-2-
targeted contrast agent, contrast enhancement is still visible
in the prostate. Furthermore, the increase in signal intensity
(wash-in rate) and the peak intensity of both the targeted
contrast agent and the non-speciﬁc contrast agent in
malignant tissue was signiﬁcantly higher than in normal
tissue [27, 29]. These experiments in animal models
showed the effectiveness and potential use of targeted
contrast agents for prostate cancer diagnosis. Unfortu-
nately, most agents use target ligands that cannot be used in
humans because of a potentially immunogenic response
due to foreign protein content in the shell of the micro-
bubble. However, a recent publication of Pochon et al.
investigated a targeted bubble using a biospeciﬁc lipo-
peptide especially designed for use in humans. They
demonstrated an avidly bound to cells expressing VEGFR2
in an in vitro human prostate cancer animal model [28].
They concluded that this targeted contrast agent therefore
opens the door to clinical use in humans.
In conclusion, pre-clinical research demonstrated the
usefulness of targeted bubbles, also in prostate cancer
animal models. Recently, reports were published describ-
ing target contrast agents designed for clinical use in
humans. Therefore, it can be expected that these new tar-
geted agents will become available for clinical testing in
short time.
Future
Not only do microbubbles give rise to many new diagnostic
imaging possibilities, as described above, but they can also
be used to transport certain substances. In ultrasound-
assisted drug delivery, microbubbles are ﬁlled with parti-
cles, e.g. drugs, siRNA, DRA, or stem cells, which then can
be released inside the tissue in the ultrasound plane with
the help of a high pressure ultrasound burst [31]. This
technique is further enhanced by sonoporation, which
temporarily increases the cell membrane permeability and,
therefore, the drug uptake. Sonoporation describes the
process by which the cell permeability is increased by
ultrasound in the presence of microbubbles [32].
Discussion
CEUS showed promising results in centers of expertise.
One of the most important ﬁndings is that with CEUS the
number of biopsies can be greatly reduced [20, 21] with a
comparable cancer detection rate. Quantiﬁcation techniques
are now developed and introduced that have the potential to
increase the accuracy of CEUS analysis and decrease the
user dependency. In this way, these techniques can help in
making CEUS also available for non-expert centers.
Targeted microbubbles for molecular imaging of pros-
tate cancer have demonstrated promising results in in vitro
as well as in vivo animal experiments. An advantage of this
technique is that after binding, for several minutes, the
whole prostate can be scanned for attached microbubbles,
and enough time is available for e.g. targeted biopsies. This
implies that with one injection of contrast, the whole
prostate can be imaged with 2D contrast-speciﬁc imaging.
One of the major targets is the VEGFR-2 receptor, which is
up-regulated in angiogenesis [27, 29]. It can therefore be
hypothesized that more aggressive and faster-growing
tumors have an increased VEGFR-2 expression. This would
make grading based on imaging possible. Focal therapy and
active surveillance are increasingly used. Molecular ultra-
sound imaging with targeted microbubbles could play a role
in selecting patients for the most appropriate treatment. For
follow-up, CEUS can also enable visualization of the
effects of therapy or medical treatments that inﬂuence the
perfusion of the prostate (Brachy, radiotherapy, HIFU,
cryoablation, or hormonal therapy) and identify early PCa
relapses that might not be detected by PSA rise [33].
Conclusion
CEUS has demonstrated excellent results in centers of
expertise.
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even further and can decrease the user-dependency, open-
ing the door to use in the routine clinical environment.
A major breakthrough in the near future will be the
clinical use of targeted microbubbles for prostate cancer
diagnosis and treatment.
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